Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: Implications for hereditary breast and/or ovarian cancer syndrome testing

Breast Cancer Research and Treatment

Volumn 145, Issue 3, 2014, Pages 707-714

  Sharma, Priyanka ^a   Klemp, Jennifer R ^a   Kimler, Bruce F ^b   Mahnken, Jonathan D ^b,c   Geier, Larry J ^a   Khan, Qamar J ^a   Elia, Manana ^a   Connor, Carol S ^b   McGinness, Marilee K ^b   Mammen, Joshua M W ^b   Wagner, Jamie L ^b   Ward, Claire ^a   Ranallo, Lori ^c   Knight, Catherine J ^c   Stecklein, Shane R ^b   Jensen, Roy A ^b,c   Fabian, Carol J ^a   Godwin, Andrew K ^b,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Genetic testing guidelines; Germline BRCA mutation; NCCN guidelines; Triple negative breast cancer

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; ASHKENAZI JEW; CANCER REGISTRY; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; GENE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; REGISTER; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84901617612     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2980-0     Document Type: Article

References (33)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinus H, Thorlacius S, Eerola H, Nevalinna H, Syrjakowski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130. doi: 10.1086/375033
2. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333. doi: 10.1200/JCO.2006.09.1066
3. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowits M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Sid LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, EMBRACE (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812-822. doi: 10.1093/jnci/djt095
4. Byrski T, Gronwald J, Huzarski T, Grzbowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379. doi: 10.1200/JCO.2008.20.7019
5. Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36:2294-2300. doi: 10.1016/S0959-8049(00)00303-8
6. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJS, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Macpherson E, Dougherty B, Jurgensmeier JM, Orr M, Matulonis U (2013) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 31:5505
7. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylansa L, Riisnaes R, Foster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Lannone R, Kaye SB, Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882-892. doi: 10.1016/S1470-2045(13) 70240-7
8. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Gerber JE (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153. doi: 10.1200/JCO.2009.22.4725
9. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244. doi: 10.1016/S0140-6736(10)60892-6
10. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65:10692-10699
11. NICE clinical guideline (2013) 164: Familial breast cancer, National Institutes for Health and Care Excellence. http://guidance.nice.org.uk/CG164. Accessed 10 April 2014
12. Balmana J, Diez O, Rubio IT, Cardoso F (2011) BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi31-vi34
13. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 12:937-948. doi: 10.1038/nrc2054
14. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Alguno AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288. doi: 10.1200/JCO.2008.16.6231
15. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE (2009) Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 33:1093-1097. doi: 10.1097/PAS.0b013e31819c1c93
16. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M (2011) Relative contributions of BRCA1 and BRCA2 mutations to "triple- negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 129:185-190. doi: 10.1007/s10549-011-1433-2
17. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485. doi: 10.1093/jnci/djg050
18. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills BG, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082-1089. doi: 10.1158/1078-0432
19. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787-2795. doi: 10.1002/cncr.26576
20. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70. doi: 10.1038/nature11412
21. Young S, Pilarski R, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakill I, Royer R, Li S, Narod SA (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86. doi: 10.1186/1471-2407-9-86
22. Meyer P, Landgraf K, Hogel B, Eiermann W, Ataseven B (2012) BRCA2 mutations and triple-negative breast cancer. PLoS One 7:e38361. doi: 10.1371/journal.pone.0038361
23. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234-1238. doi: 10.1038/bjc.2012.31
24. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast and Ovarian, (ed 4.2013), National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp. Accessed 10 April 2014
25. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 27:4214-4220. doi: 10.1200/JCO.2010.28.0719
26. Wang G, Beattie MS, Ponce NA, Phillips KA (2011) Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med 13:1045-1050. doi: 10.1097/GIM.0b013e31822a8113
27. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795. doi: 10.1200/JOP.777003
28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381. doi: 10.1016/j.jbi.2008.08.010
29. U. S. Census Bureau (2010) Census Data, 2010 Census Briefs. http://www.census.gov/2010census/data/. Accessed 10 April 2014
30. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 5:893-901. doi: 10.1200/JCO.2009.27.0660
31. American Society of Breast Surgeons (2012) Position Statement on BRCA Genetic Testing for Patients With and Without Breast Cancer. American Society of Breast Surgeons. https://www.breastsurgeons.org/statements/PDF-Statements/BRCA- Testing.pdf. Accessed 11 April 2014
32. Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmans T (2013) NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 22:155-163. doi: 10.1007/s10897-012-9547-1
33. US Preventive Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation. Ann Intern Med 143:355-361. doi: 10.7326/0003-4819-143-5-200509060-00011